<p>Certara（纳斯达克代码：CERT - 获取免费报告）在周五发布的研究报告中，罗伯特·W·贝尔德的研究分析师将其目标价格从 9.00 美元上调至 13.00 美元，Benzinga 报道。该券商目前对该股票的评级为 “中性”。罗伯特·W·贝尔德的价格目标暗示该公司当前价格有 23.69% 的潜在上涨空间。</p>
<ul>
<li>尽管每股收益超预期，Simulations Plus 股票下跌 15%</li>
</ul>
<p>CERT 还成为其他几份报告的主题。斯蒂芬斯在 2 月 27 日的报告中重申了 “增持” 评级，并将 Certara 的目标价格设定为 17.00 美元。TD Cowen 在 2 月 27 日的报告中开始覆盖 Certara 的股票。他们对该股票给予了 “买入” 评级，并设定了 16.00 美元的目标价格。威廉·布莱尔在 2 月 27 日的报告中重申了 Certara 的 “市场表现” 评级。最后，巴克莱在一份报告中将 Certara 的目标价格从 13.00 美元下调至 11.00 美元，并对该股票设定了 “等权重” 评级。四位研究分析师对该股票给予了持有评级，四位则给予了买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 15.50 美元。</p>
<p><strong>查看我们对 CERT 的最新分析</strong></p>
<h2>Certara 股票表现</h2>
<ul>
<li>这三只小型动量股票是否正在酝酿大涨？</li>
</ul>
<p>Certara 股票在周五开盘价为 10.51 美元。该股票的 50 日移动平均价格为 11.63 美元，200 日移动平均价格为 11.35 美元。Certara 的 52 周低点为 8.64 美元，52 周高点为 18.68 美元。该公司的市值为 16.9 亿美元，市盈率为-52.55，PEG 比率为 9.29，贝塔值为 1.64。该公司的流动比率为 2.86，速动比率为 2.86，债务与股本比率为 0.28。</p>
<h2>对 Certara 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近对 CERT 的持仓进行了调整。Versant Capital Management Inc 在第一季度将其在 Certara 的持股增加了 218.8%。Versant Capital Management Inc 现在拥有 2719 股该公司的股票，价值 27000 美元，此前在上个季度购买了 1866 股。Venturi Wealth Management LLC 在第四季度将其在 Certara 的持仓增加了 839.1%。Venturi Wealth Management LLC 现在拥有 2808 股该公司的股票，价值 30000 美元，此前在此期间购买了 2509 股。富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Certara 的持股增加了 48.4%。富国银行现在拥有 3208 股该公司的股票，价值 34000 美元，此前在上个季度购买了 1047 股。约翰逊金融集团（Johnson Financial Group Inc.）在第四季度购买了 Certara 的新股份，价值约 47000 美元。最后，Blue Trust Inc.在第四季度将其在 Certara 的持仓增加了 20.9%。Blue Trust Inc.现在拥有 4747 股该公司的股票，价值 56000 美元，此前在上个季度增加了 822 股。机构投资者和对冲基金持有该公司 73.96% 的股票。</p>
<h2>关于 Certara</h2>
<p>（获取免费报告）</p>
<ul>
<li>Certara 股票是关键的生物模拟投资</li>
</ul>
<p>Certara, Inc 及其子公司为客户提供软件产品和技术驱动的服务，支持药物发现、临床前和临床研究、监管提交以及美国及国际市场准入的生物模拟。它提供基于模型的药物开发解决方案，以及用于预测药物动力学和药效学的生物模拟解决方案。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Certara 更好</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>IAMGOLD 股票因转型故事获得关注而上涨</li>
<li>在 52 周高点盈利交易股票</li>
<li>即使油价暴跌，3 只能源股票仍然获胜</li>
<li>内幕交易 - 您需要知道的事项</li>
<li>美光因关税威胁下跌：风险/回报前景改善</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1000 美元在 Certara 吗？</h2>
<p>在您考虑 Certara 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Certara 并不在名单上。</p>
<p>尽管 Certara 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CERT

<p>罗伯特·W·贝尔德将 Certara 的目标股价从 9.00 美元上调至 13.00 美元，维持 “中性” 评级。这表明与当前价格相比，潜在上涨幅度为 23.69%。其他分析师的评级各不相同，普遍评级为 “适度买入”，平均目标股价为 15.50 美元。Certara 的股票开盘价为 10.51 美元，52 周价格区间为 8.64 美元至 18.68 美元。机构投资者持有该股票的 73.96%，显示出对公司的强烈兴趣</p>

<p>Certara (NASDAQ:CERT - Get Free Report) had its target price boosted by research analysts at Robert W. Baird from $9.00 to $13.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a &#34;neutral&#34; rating on the stock. Robert W. Baird's price objective suggests a potential upside of 23.69% from the company's current price.</p>
<div class="lb-trans"><p>Certara（纳斯达克代码：CERT - 获取免费报告）在周五发布的研究报告中，罗伯特·W·贝尔德的研究分析师将其目标价格从 9.00 美元上调至 13.00 美元，Benzinga 报道。该券商目前对该股票的评级为 “中性”。罗伯特·W·贝尔德的价格目标暗示该公司当前价格有 23.69% 的潜在上涨空间。</p>
</div><ul>
<li>Simulations Plus Stock Drops 15% Despite EPS Beat</li>
</ul>
<div class="lb-trans"><ul>
<li>尽管每股收益超预期，Simulations Plus 股票下跌 15%</li>
</ul>
</div><p>CERT has been the topic of several other reports. Stephens reiterated an &#34;overweight&#34; rating and set a $17.00 price objective on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on shares of Certara in a report on Thursday, February 27th. They issued a &#34;buy&#34; rating and a $16.00 price target on the stock. William Blair restated a &#34;market perform&#34; rating on shares of Certara in a report on Thursday, February 27th. Finally, Barclays reduced their target price on Certara from $13.00 to $11.00 and set an &#34;equal weight&#34; rating on the stock in a report on Thursday. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $15.50.</p>
<div class="lb-trans"><p>CERT 还成为其他几份报告的主题。斯蒂芬斯在 2 月 27 日的报告中重申了 “增持” 评级，并将 Certara 的目标价格设定为 17.00 美元。TD Cowen 在 2 月 27 日的报告中开始覆盖 Certara 的股票。他们对该股票给予了 “买入” 评级，并设定了 16.00 美元的目标价格。威廉·布莱尔在 2 月 27 日的报告中重申了 Certara 的 “市场表现” 评级。最后，巴克莱在一份报告中将 Certara 的目标价格从 13.00 美元下调至 11.00 美元，并对该股票设定了 “等权重” 评级。四位研究分析师对该股票给予了持有评级，四位则给予了买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 15.50 美元。</p>
</div><p><strong>View Our Latest Analysis on CERT</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CERT 的最新分析</strong></p>
</div><h2>Certara Stock Performance</h2>
<div class="lb-trans"><h2>Certara 股票表现</h2>
</div><ul>
<li>Are These 3 Small Momentum Stocks Setting Up Big Gains?</li>
</ul>
<div class="lb-trans"><ul>
<li>这三只小型动量股票是否正在酝酿大涨？</li>
</ul>
</div><p>Certara stock opened at $10.51 on Friday. The stock has a fifty day moving average price of $11.63 and a 200 day moving average price of $11.35. Certara has a 52 week low of $8.64 and a 52 week high of $18.68. The firm has a market capitalization of $1.69 billion, a P/E ratio of -52.55, a PEG ratio of 9.29 and a beta of 1.64. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.</p>
<div class="lb-trans"><p>Certara 股票在周五开盘价为 10.51 美元。该股票的 50 日移动平均价格为 11.63 美元，200 日移动平均价格为 11.35 美元。Certara 的 52 周低点为 8.64 美元，52 周高点为 18.68 美元。该公司的市值为 16.9 亿美元，市盈率为-52.55，PEG 比率为 9.29，贝塔值为 1.64。该公司的流动比率为 2.86，速动比率为 2.86，债务与股本比率为 0.28。</p>
</div><h2>Hedge Funds Weigh In On Certara</h2>
<div class="lb-trans"><h2>对 Certara 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently made changes to their positions in CERT. Versant Capital Management Inc increased its holdings in Certara by 218.8% in the 1st quarter. Versant Capital Management Inc now owns 2,719 shares of the company's stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after buying an additional 2,509 shares during the period. Wells Fargo &amp; Company MN grew its stake in shares of Certara by 48.4% in the fourth quarter. Wells Fargo &amp; Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Certara during the 4th quarter valued at about $47,000. Finally, Blue Trust Inc. lifted its position in Certara by 20.9% during the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock worth $56,000 after acquiring an additional 822 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近对 CERT 的持仓进行了调整。Versant Capital Management Inc 在第一季度将其在 Certara 的持股增加了 218.8%。Versant Capital Management Inc 现在拥有 2719 股该公司的股票，价值 27000 美元，此前在上个季度购买了 1866 股。Venturi Wealth Management LLC 在第四季度将其在 Certara 的持仓增加了 839.1%。Venturi Wealth Management LLC 现在拥有 2808 股该公司的股票，价值 30000 美元，此前在此期间购买了 2509 股。富国银行（Wells Fargo &amp; Company MN）在第四季度将其在 Certara 的持股增加了 48.4%。富国银行现在拥有 3208 股该公司的股票，价值 34000 美元，此前在上个季度购买了 1047 股。约翰逊金融集团（Johnson Financial Group Inc.）在第四季度购买了 Certara 的新股份，价值约 47000 美元。最后，Blue Trust Inc.在第四季度将其在 Certara 的持仓增加了 20.9%。Blue Trust Inc.现在拥有 4747 股该公司的股票，价值 56000 美元，此前在上个季度增加了 822 股。机构投资者和对冲基金持有该公司 73.96% 的股票。</p>
</div><h2>About Certara</h2>
<div class="lb-trans"><h2>关于 Certara</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Certara Stock is Key Biosimulation Play</li>
</ul>
<div class="lb-trans"><ul>
<li>Certara 股票是关键的生物模拟投资</li>
</ul>
</div><p>Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.</p>
<div class="lb-trans"><p>Certara, Inc 及其子公司为客户提供软件产品和技术驱动的服务，支持药物发现、临床前和临床研究、监管提交以及美国及国际市场准入的生物模拟。它提供基于模型的药物开发解决方案，以及用于预测药物动力学和药效学的生物模拟解决方案。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Certara</li>
<li>What Investors Need to Know About Upcoming IPOs</li>
<li>IAMGOLD Stock Climbs as Turnaround Story Gains Traction</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>3 Energy Stock Winners Even as Oil Prices Plunge</li>
<li>Insider Trading - What You Need to Know</li>
<li>Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Certara 更好</li>
<li>投资者需要了解即将上市的 IPO</li>
<li>IAMGOLD 股票因转型故事获得关注而上涨</li>
<li>在 52 周高点盈利交易股票</li>
<li>即使油价暴跌，3 只能源股票仍然获胜</li>
<li>内幕交易 - 您需要知道的事项</li>
<li>美光因关税威胁下跌：风险/回报前景改善</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VSVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=CERT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Certara Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1000 美元在 Certara 吗？</h2>
</div><p>Before you consider Certara, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Certara 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Certara wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Certara 并不在名单上。</p>
</div><p>While Certara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Certara 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Certara（纳斯达克代码：CERT）的目标价格上调至 13.00 美元